With the ambition to become the leading clinical oligonucleotide research company in Sweden, Ribocure Pharmaceuticals AB established Ribocure Clinic, with a vision to drive excellence in proof of principle/concept clinical trials with an in-house high volume and high quality Ph2 clinical trial unit.
Now the first patient has been enrolled in a deep phenotyping study paving the way to identify “right patients” to “right interventional trial”, a precision medicine approach that represents one of the important cornerstones in our effort driving clinical excellence.
Ribocure Clinic is a Ph2 clinical trial unit situated at the company’s premises at GoCo Clinic in Gothenburg, Sweden. Here, patients are welcomed to clinical trial participation by experienced and highly trained medical research staff specialized in clinical trial execution, in particular complex Ph2 trial endpoints in cardiovascular, pulmonary, renal and liver areas where advanced imaging and functional assessments are required. It is a remarkable achievement that it took less than two working months from our move to GoCo Clinic, until we established all SOPs as well as received all necessary certificates and permissions from various authorities, and finally the official First-Patient-In status. This milestone reflects the professionalism, dedication and efficiency of our high-performing clinical team.
Ribocure Pharmaceuticals would also like to highlight the dedicated teams at data management and quality assurance who have put relentless effort into making this milestone a reality.